Eli Lilly Signs $2.75 Billion AI Drug Development Deal with Insilico Medicine
US pharmaceutical giant Eli Lilly has entered a $2.75 billion partnership with Hong Kong-listed AI drug developer Insilico Medicine, marking one of the largest AI-pharma deals to date.
·1 source
